52nd week of 2010 patent applcation highlights part 43 |
Patent application number | Title | Published |
20100329968 | PROCESS FOR THE RECOVERY OF SELENIUM FROM MINERALS AND/OR ACIDIC SOLUTIONS - A process and method for recovering elemental selenium, selenite or selenate from minerals and selenium salts solutions using a reducing sugar to reduce selenium before precipitating the elemental selenium, selenite and/or the selenate. | 2010-12-30 |
20100329969 | PROCESS FOR THE RECOVERY OF SELENIUM FROM MINERALS AND/OR ACIDIC SOLUTIONS - A process and method for recovering elemental selenium, selenite or selenate from minerals and selenium salts solutions using a reducing sugar to reduce selenium before precipitating the elemental selenium, selenite and/or the selenate. | 2010-12-30 |
20100329970 | METHOD FOR RECOVERY OF COPPER, INDIUM, GALLIUM, AND SELENIUM - A method for the recovery of copper, indium, gallium, and selenium is provided. The method includes steps of using a mixed solution containing a hydrochloric acid and hydrogen peroxide to dissolve the copper, indium, gallium, and selenium. After using the hydrazine to separate the selenium out, the copper is reduced by indium metal. Later, a combination of a supported liquid membrane (SLM) and a strip dispersion solution separates the gallium from the indium. The acid performed in all the steps of the method is hydrochloric acid. Therefore, the copper, indium, gallium, and selenium can be separated one by one in a single production line without changing the solution during the operation process, thereby simplifying the process, shortening the operation time and lowering the manufacture cost. | 2010-12-30 |
20100329971 | NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY THE METHOD - Disclosed is a novel hydroxy radical generation method which relies on a novel scientific fact relating to the generation of a hydroxy radical and the inactivation of a virus. Also disclosed is an anti-viral material produced by utilizing the method. The anti-viral material comprises a metal oxide powder and a hydroxide which enable the generation of a hydroxy radical that can inactivate a virus. An virus can be inactivated by the action of the hydroxy radical generated from the anti-viral material. | 2010-12-30 |
20100329972 | COOKING OVEN WITH OXYGENATING MEANS AND METHOD FOR OPERATING SAME - The invention relates to a cooking oven ( | 2010-12-30 |
20100329973 | METHOD AND APPARATUS FOR FORMING ZINC OXIDE - Provided is a method for forming zinc oxide which includes introducing a zinc vapor and a water vapor to a reactor; providing a zinc particulate to the reactor to promote the reaction between the zinc vapor and water vapor, thereby forming zinc oxide and hydrogen. An apparatus for forming zinc oxide is also provided. | 2010-12-30 |
20100329974 | HYDROGEN STORAGE MATERIAL AND A PROCESS FOR RELEASE OF HYDROGEN - There is disclosed a hydrogen storage material which may comprise an optionally substituted M-amino-borane complex or a composite comprising: (i) at least one of a M-nitrogen compound; and (ii) a compound comprising (Y—Z)—R bonds. M is a metal or metalloid; Y is an element selected from Group 13 of the Periodic Table of Elements; Z is an element selected from Group 15 of the Periodic Table of Elements; and R is hydrogen (H) or a hydrocarbyl. | 2010-12-30 |
20100329975 | Cordierite-Forming Compositions With Hydratable Alumina And Methods Therefor - A cordierite batch composition that includes a hydratable alumina, as defined herein. The hydratable alumina, when hydrated, can provide additional strength to shaped batch compositions at temperatures below those used to fire the compositions. Methods are also provided for forming cordierite ceramic articles from the cordierite batch compositions. | 2010-12-30 |
20100329976 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 2010-12-30 |
20100329977 | METHOD FOR IMAGING TUMOR TISSUE - A method is disclosed for imaging a tumor tissue, wherein in at least one embodiment a) the tumor tissue is contacted with a monoclonal antibody, an antigen-binding fragment thereof, a recombinant binding protein, an aptamer, or other molecule, each of which recognizes and binds at least one neoepitope which has been generated by proteolytic cleavage of proteins surrounding the tumor tissue by tumor-specific proteases, and b) the complexes formed from neoepitope and monoclonal antibody, antigen-binding fragment thereof, recombinant binding protein, aptamer, or other molecule are depicted with an imaging method, and also to neoepitopes generated by proteolytic cleavage of surrounding proteins by tumor-specific proteases, and also proteins or peptides for generating neoepitopes by tumor-specific proteases. | 2010-12-30 |
20100329978 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS - Compounds having the general formula II, III, or IV | 2010-12-30 |
20100329979 | Method and Composition to Evaluate Cytochrome P450 2D6 Isoenzyme Activity Using a Breath Test - The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of | 2010-12-30 |
20100329980 | HUMANIZED ANTI-ALPHA 9 INTEGRIN ANTIBODIES AND THE USES THEREOF - The present invention provides humanized antibodies that immunospecifically recognize human α9 integrin. Some of these antibodies inhibit the biological functions of the α9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with α9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth. | 2010-12-30 |
20100329981 | SIMPLIFIED AND IMPROVED METHOD FOR PREPARING AN ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOME FOR SYSTEMIC ADMINISTRATION OF A THERAPEUTIC OR DIAGNOSTIC AGENT - A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex. | 2010-12-30 |
20100329982 | PARTICLES WITH INDUCIBLE CHANGE OF SHAPE - The invention relates to particles which exhibit a stimulable shape change and allow control of their uptake in active cells. The particles can be used as carrier systems for bioactive molecules or as diagnostic agents, and the spherical shape thereof has a size permitting uptake in a cell. Each particle assumes a temporary, non-spherical and thus non-uptakeable or only slightly uptakeable shape which can be transformed into a spherical and thus uptakeable shape by a suitable stimulus. | 2010-12-30 |
20100329983 | COMPOUNDS AND METHODS FOR THE DETECTION OF TRPV-6 CANCERS AND DRUG DELIVERY - Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6. | 2010-12-30 |
20100329984 | RESPIRATORY DISPERSION FOR METERED DOSE INHALERS - A respiratory dispersion for pulmonary delivery comprises one or more bioactive agents, a suspension medium, and a plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 μm. The suspension medium comprises at least one propellant and permeates the perforated microstructures. | 2010-12-30 |
20100329985 | TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES - The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used. | 2010-12-30 |
20100329986 | Adult Hepatic Progenitor Cells and Methods of Use Thereof - Compositions and methods effective for identifying, isolating, and utilizing adult hepatic progenitor cells are provided. | 2010-12-30 |
20100329988 | Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide - The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance. | 2010-12-30 |
20100329989 | In Vivo Labeling of Mammalian Cone Photoreceptors by Intravitreal Injection of Fluorescently Tagged Peanut Agglutinin - A method for specifically labeling of mammalian cone photoreceptors in vivo comprising injecting a mammal with peanut agglutinin conjugated with a fluorescent probe. The peanut agglutinin labels the cone photoreceptor. | 2010-12-30 |
20100329990 | LUMINESCENT MARKERS - The invention relates to luminescent proteins, nucleic acids encoding same, compositions and combinations comprising the proteins, and methods using the proteins, nucleic acids, compositions and combinations. In particular, a luminescent protein is provided comprising oncomodulin in which a salt bridge has been introduced to provide greater stability. The protein may be used as a luminescent marker in, for example, luminescent items, immunoassays, and fluorescent energy transfer assays. | 2010-12-30 |
20100329991 | Medicinal preparation particularly for the treatment of slipped discs hernias - The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas. | 2010-12-30 |
20100329992 | SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB3 EXPRESSING TUMORS - The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb | 2010-12-30 |
20100329993 | METHOD OF FIXING AND EXPRESSING PHYSIOLOGICALLY ACTIVE SUBSTANCE - The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ. | 2010-12-30 |
20100329994 | Use of Deuterium Dioxide for Treating Hyperproliferative Skin Diseases - The invention relates to D | 2010-12-30 |
20100329995 | COMPOSITIONS CONTAINING LACTOFERRIN, AND METHODS OF USING SAME TO PROMOTE GROWTH OF SKIN CELLS - The present invention relates, generally, to compositions including lactoferrin, and to compositions including both lactoferrin and lysozyme. The present invention also includes topical formulations containing the compositions, methods of making the formulations, methods of using the formulations to treat various skin disorders/conditions, to treat wounds, and to methods of producing artificial skin using the composition, and methods of treating burns using the formulation, optionally in conjunction with the application of artificial skin. | 2010-12-30 |
20100329996 | Novel Combination of Therapeutic Agents - Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist and/or a corticosteroid for inhaled administration via the nose or mouth, and methods of using them are provided herein. | 2010-12-30 |
20100329997 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION - The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system. | 2010-12-30 |
20100329998 | NOVEL HETEROCYCLES - Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases. | 2010-12-30 |
20100329999 | Antiperspirant Aerosol Composition - According to a first aspect, antiperspirant aerosol compositions are disclosed comprising antiperspirant active particulates, a propellant and at least 5% by weight of the entire antiperspirant aerosol composition of a silicone component, wherein (a) the antiperspirant active particulates are the only particulates in the antiperspirant aerosol composition; (b) the silicone component comprises one or more silicones and the or each silicone is a non-volatile silicone. According to a second aspect, packaged antiperspirant aerosol compositions according to the first aspect are disclosed. | 2010-12-30 |
20100330000 | ENZYMES FOR TREATMENT OF GINGIVITIS - The invention relates to a method for treating, controlling and/or preventing diseases of the oral cavity, particularly diseases and disorders induced accumulation of plaque, by administering a chewing gum composition comprising at least one krill enzyme. Specifically, the invention is directed to a method for preventing, treating and controlling the development of gingivitis, gum disease and symptoms thereof using a composition having a krill enzyme concentration of about 0.005 U/g to about 0.05 U/g of the chewing gum composition. | 2010-12-30 |
20100330001 | ANTIBACTERIAL COMPOSITIONS - The present invention relates to oral antibacterial compositions comprising trihydroxybenzoate derivatives, e.g., useful for the treatment of gum diseases (e.g., gingivitis or periodontitis) and to methods of using such compositions. | 2010-12-30 |
20100330002 | COMPOSITIONS AND METHODS COMPRISING BASIC AMINO ACID PEPTIDES AND PROTEASES - The present invention is directed to compositions comprising peptides comprising a basic amino acid. e.g., arginine, and a protease. | 2010-12-30 |
20100330003 | ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF - This invention relates to methods of treating early enamel lesions comprising applying an effective amount of a basic amino acid in free or salt form, together with fluoride to a patient in need thereof. | 2010-12-30 |
20100330004 | Non-Petrochemically Derived Cationic Emulsifiers That are Neutralized Amino Acid Esters and Related Compositions and Methods - The invention includes a method of increasing the substantivity of a personal care composition to hair, skin or nails by preparing a composition of an aqueous phase, a non-aqueous phase and a neutralized amino acid ester that is a reaction product of a neutral amino acid having a non-polar side chain with a long chain fatty alcohol and is represented by formula (I): | 2010-12-30 |
20100330005 | DENTAL ORAL COMPOSITION - A dental composition for oral use, containing a phosphorylated saccharide (a), a polyphosphoric acid and/or a salt thereof (b), and a cationic bactericidal agent (c), wherein a ratio of a total amount of the phosphorylated saccharide (a) and the polyphosphoric acid and/or a salt thereof (b) contained to an amount of the cationic bactericidal agent (c) contained, i.e. {(a)+(b)}/(c), is from 0.05 to 20 in a weight ratio. The dental composition for oral use of the present invention can be suitably used for an oral cavity cleaning agent, including dentifrice agents such as a paste dentifrice agent, a powder dentifrice agent, and a liquid dentifrice agent, a mouse-wash agent, a troche, a tablet, a cream, an ointment, a bonding agent, a mouth spray, a coating agent to tooth surface or a dental prosthetic, a hypersensitive inhibitor, a therapeutic agent for periodontal diseases, that is applied to a periodontal pocket, wet tissue for oral cavity care, an oral refreshing agent, chewing gum, or a gargling agent, or the like. | 2010-12-30 |
20100330006 | Antimicrobial lotion compositions - Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer. | 2010-12-30 |
20100330007 | Imrpoved Skin Brightening Compositions - An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an ability to lighten mammalian skin color and is nonirritating. The composition contains (a) a retinoid loaded onto polymeric microparticles and (b) a second skin lightening agent, like kojic acid or a derivative thereof, such as kojic dipalmitate. | 2010-12-30 |
20100330008 | Core-Shell Type Zinc Oxide Microparticle or Dispersion Containing the Microparticle, and Production Process and Use of the Microparticle or the Dispersion - The objects of the present invention are to provide core-shell type zinc oxide microparticles, a dispersion containing such microparticles, and a production process and uses of the microparticles and the dispersion, and the invention is directed at: core-shell type zinc oxide microparticles having an average particle diameter of from 50 to 1,000 nm, wherein a core is a secondary particle of spherical shape to the surface of which a polymer is attached as a shell; a dispersion of such zinc oxide microparticles; a dry powder obtained from such a zinc oxide microparticle dispersion; a process for producing core-shell type zinc oxide microparticles or a dispersion thereof, which process includes the steps of: mixing together a zinc salt and a polymer in an organic solvent so as to obtain a mixture; and heating/refluxing the mixture at a predetermined temperature so as to cause core-shell type zinc oxide microparticles to precipitate, wherein the zinc salt is zinc acetate; and uses such as cosmetics, resins and fibers which contain the core-shell type zinc oxide microparticles and have an ultraviolet light blocking action. | 2010-12-30 |
20100330009 | COUMESTAN-LIKE ANTIOXIDANTS AND UV ABSORBANTS - The present invention relates to derivatives of the 1H-pyrano[4,3-b]benzofuran-1-one structure and their nitrogen analogues which possess powerful antioxidant properties combined with a highly effective UV absorbing functionality in one molecule. These compounds are especially useful in cosmetical and dermatological formulations. | 2010-12-30 |
20100330010 | COMPOSITION AND METHOD FOR REDUCING HARMFUL EFFECTS OF ULTRAVIOLET RADIATION IMPINGING ON THE SKIN - A composition is provided that is suitable for topical administration for the treatment of skin to reduce the harmful effects of ultraviolet radiation impinging on the skin, the composition comprising acetylsalicylic acid and sodium bicarbonate. Also provided is a method for treating skin to reduce the harmful effects of ultraviolet radiation impinging on the skin comprising topically administering to the skin a therapeutically effective amount of a composition comprising acetylsalicylic acid and sodium bicarbonate. Also provided is an aqueous composition suitable as an additive to a composition of cosmetics comprising acetylsalicylic acid and sodium bicarbonate. Also provided is a method of manufacturing a cosmetic composition, comprising obtaining an aqueous composition that includes acetylsalicylic acid and sodium bicarbonate, and combining the aqueous composition with cosmetic ingredients to create the cosmetic composition. | 2010-12-30 |
20100330011 | Silicone-Organic Gels with Polyalkyloxylene Crosslinked Silicone Elastomers - Silicone organic gels and gel paste compositions are disclosed containing a silicone organic elastomer in a carrier fluid. The silicone organic elastomer is a reaction product of a linear or branched organohydrogensiloxane, an α, ω-unsaturated polyoxyalkylene, and a hydrosilylation catalyst. The silicone organic elastomer is particularly useful to ge! organic earner fluids, The gels and gels pastes also provide enhanced compatibility with many personal and health care actives. | 2010-12-30 |
20100330012 | HYDRATING CREAM FOUNDATION IN EMULSION FORM - The present invention is directed to a cosmetic composition that is moisturizing, hydrating, refreshing and long wearing, and has an unique texture and feel comprising a cellulosic gelling agent, an oil-soluble polar modified polymer, and water. | 2010-12-30 |
20100330013 | AMADORIASES IN WASHING AND CLEANING PRODUCTS - Body care products, hair care products, shampoos, oral care, dental care and dental prosthesis care products, dental brace care products, cosmetics, therapeutics, washing agents, cleaning agents, brightening products, disinfectants, rinsing agents, hand washing products, dishwashing agents, machine dishwashing agents and agents for the bleaching and disinfecting treatment of filter media, textiles, furs, paper, skins or leather, and other products containing amadoriases are provided. Also, the use of amadoriases for decomposition products of the Amadori rearrangement is provided. | 2010-12-30 |
20100330014 | COMPOSITION FOR EXTERNAL APPLICATION ON SKIN, AND SKIN-WHITENING COSMETIC - An object of the present invention is to provide a composition for external application on the skin containing hydroquinone as an active ingredient, which has an excellent skin-whitening activity and reduced side effects. The composition for external application on the skin of the present invention as a means for achieving the object is characterized by containing hydroquinone or a derivative thereof compounded with a lyotropic liquid crystal. | 2010-12-30 |
20100330015 | COMPOSITION COMPRISING A POLYOL, A SUGAR SILICONE SURFCTANT AND A OIL-SOLUBLE HIGH CARBON POLAR MODIFIED POLYMER - The invention relates to a composition comprising a oil-soluble high carbon polar modified polymer, a sugar silicone surfactant and a hyperbranched polyol. | 2010-12-30 |
20100330016 | COMPOSITION COMPRISING A POLYOL AND A OIL-SOLUBLE HIGH CARBON POLAR MODIFIED POLYMER - The invention relates to a composition comprising an oil-soluble high carbon polar modified polymer and a hyperbranched polyol. | 2010-12-30 |
20100330017 | ENHANCED SHINE AND MOISTURE LIP COMPOSITION - The present invention is directed to enhanced shine and moisturizing aqueous lip compositions with a unique texture and feel. The compositions include: (a) at least one sugar silicone surfactant; (b) at least one polyamine; (c) at least one high carbon polar modified polymer; and (d) water. | 2010-12-30 |
20100330018 | COMPOSITION CONTAINING A SUPERABSORBENT POLYMER AND AN ORGANIC UV SCREENING AGENT - A composition in the form of an emulsion containing an aqueous phase, a fatty phase, a superabsorbent polymer, and an organic UV screening agent. Method for the treatment of a keratinous substance whereby the composition described is applied to the keratinous substance. | 2010-12-30 |
20100330019 | KERATIN DERIVATIVES AND METHODS OF MAKING THE SAME - Soluble keratin derivatives are disclosed. The soluble keratin derivatives may include a soluble keratin protein having at least one substituted chemical group at a lysine group, terminal amine group and/or hydroxyl amino acid group of a soluble keratin protein. Soluble keratin derivatives may be formed by succinylation or quaternisation, or by reaction with fatty acid derivatives. The soluble keratin derivatives may be used in personal care formulations, and may also comprise mixtures of several different soluble keratin derivatives. | 2010-12-30 |
20100330020 | Aminosilicone Containing Detergent Compositions and Methods of Using Same - The instant disclosure relates to cleaning and/or treatment compositions, such as fabric care, hair care and skin care compositions, containing an aminosilicone, one or more anionic surfactants and one or more deposition aids. The disclosed compositions have improved rheology and performance. The disclosed compositions may provide one or more fabric care benefits including, for example, fabric softness and/or an anti-wrinkle benefit. Methods of making and using the compositions are also disclosed. | 2010-12-30 |
20100330021 | SUBSTITUTED (THIAZOL-2-YL)-AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES - Compounds of the formula | 2010-12-30 |
20100330022 | REFRESHING CREAM FOUNDATION IN GEL FORM - The present invention is directed to a cosmetic composition includes (a) at least one sugar silicone surfactant; (b) at least one polyamine; (c) at least one oil-soluble polar modified polymer; (d) at least one gelling agent; (e) at least one hyperbranched polyol; and (f) water. | 2010-12-30 |
20100330023 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same - The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents. | 2010-12-30 |
20100330024 | HYDRATING COMPOSITIONS - The present invention is directed to compositions including at least one sugar silicone surfactant, at least one polyamine; at least one oil-soluble polar modified polymer, and water. | 2010-12-30 |
20100330025 | Surface Independent, Surface-Modifying, Multifunctional Coatings and Applications Thereof - The invention provides surface treatments that reduce or eliminate marine biofouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface. | 2010-12-30 |
20100330026 | ORGANIC POLYMERIC PHOTON UP-CONVERSION NANOPARTICLES FOR BIOLOGICAL APPLICATIONS - The present invention relates to organic polymeric photon up-conversion nanoparticles for biological applications, such as labeling and/or detection of cells, biological (macro-) molecules or other analytes, as well as for sensing temperature, pressure, oxygen and other substances that influence the up-conversion process. It further relates to organic photon up-conversion nanoparticles for singlet oxygen generation and the treatment of diseases, such as cancer. | 2010-12-30 |
20100330027 | Cyanoacrylate Initiator System - The present invention is directed to curable compositions that comprise a non-porous substrate, one or more cyanoacrylate polymerization initiators and a prepolymer composition comprising at least one liquid cyanoacrylate monomer or mixture of such monomers (solid or liquid) and/or cyanoacrylate oligomers. The non-porous substrate is a collection of individual particulates that are not bound, bonded or fixed to one another. At least one initiator is deposited on the surface of the individual particulates to form a plurality of initiator carriers. The prepolymer composition receives the plurality of initiator carriers to begin a controlled and consistent polymerization or curing of the liquid cyanoacrylate monomer in order to produce a biocompatible adhesive composition for use on living tissue. The present invention also provides for methods of making and using and devices for such a curable compositions, particularly in treating living tissue by applying to living tissue a biocompatible adhesive composition. | 2010-12-30 |
20100330028 | COMBINATION THERAPY FOR CHRONIC DERMAL ULCERS - Disclosed is a method of promoting healing of a chronic dermal ulcer, such as a diabetic ulcer, in a subject. The method comprises administering to the subject a combination one or more agonists of the non-proteolytically activated thrombin receptor and one or more angiogenic growth factors. | 2010-12-30 |
20100330029 | Cancer Treatments with Radiation and Immunocytokines - The present invention is directed to a method for treating tumors and cancer cells by administering an immunocytokine following radiation treatment. This combination of treatments can stimulate an immune response at irradiated and non-irradiated sites, which is useful in eradicating cancer cells that have spread from the site of the primary tumor. In addition, immunocytokines can be administered at a dose that is less that the maximum tolerated dose, which reduces the side effects associated with immunocytokine therapy. | 2010-12-30 |
20100330030 | Vasculostatic Agents and Methods of Use Thereof - Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. | 2010-12-30 |
20100330031 | POLYPEPTIDE HAVING AN IMPROVED CYTOSINE DEAMINASE ACTIVITY - The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity. | 2010-12-30 |
20100330032 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein R | 2010-12-30 |
20100330033 | Protein-carrier conjugates - The invention provides compositions and methods for covalent attachment of polymer and lipid carriers to therapeutic proteins to form carrier-protein conjugates having linkers between the carrier and protein portions of the conjugates. The linkers are selected to minimize steric effects. The linkers reduce the shielding effect of the carrier on the therapeutic protein and also allow better access for enzymatic or chemical cleavage of the carbamate bond. The linkers attach to the therapeutic protein via a carbamate bond and are either directly adjacent to the carbamate bond or are separated by a single carbon having a nitrogen side chain. Such linkers are solely comprised of carbon, sulfur and hydrogen and are between four and ten atoms (either C or S) in length. | 2010-12-30 |
20100330034 | USE OF BISPECIFIC ANTIBODIES TO REGULATE IMMUNE RESPONSES - The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor. | 2010-12-30 |
20100330035 | Pharmaceutical Compositions for Treatment of HCV Patients that are Poor-Responders to Interferon - The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate. | 2010-12-30 |
20100330036 | MARKERS OF MATRIX GENE EXPRESSION AND CELLULAR DIFFERENTIATION IN CHONDROCYTES - The invention relates generally to the field of tissue engineering. More particularly, the present invention relates to methods for identifying a population of cells suitable for the repair of connective tissue, including cartilage. The invention further provides methods and compositions related to the generation of a population of cells suitable for the repair of cartilage, in particular in the repair of cartilage degeneration associated with osteoarthritis. Methods of using said cells thus identified or thus generated, in methods to extend the period of cell manipulation, i.e. to increase the yield of cells suitable in the aforementioned methods, are also provided by the present invention. | 2010-12-30 |
20100330037 | ADENOVIRAL SYSTEMS AND THE USES THEREOF - The invention is related to a nucleic acid comprising an adenoviral nucleic acid, which also comprises a nucleic acid sequence coding for YB-1. | 2010-12-30 |
20100330038 | METHODS FOR EXPRESSING PROTEINS IN AXONS - The invention relates to expressing proteins in the axons of mammalian polypeptide in neuronal axons, viruses that can be used deliver nucleic acids of the invention into neuronal axons, as well as methods for doing so. Thus, the invention provides pharmaceutical compositions comprising viruses of the invention, as well as their use in methods of treating injured axons or conditions associated with aberrant axon growth or function. | 2010-12-30 |
20100330039 | Schizochytrium Fatty Acid Synthase (FAS) and Products and Methods Related Thereto - Disclosed are a fatty acid synthase (FAS) from | 2010-12-30 |
20100330040 | COMPOSITION WITH SYNBIOTICS - Nutritional compositions with health benefits comprising bacterial strains and galactooligosaccharides are disclosed. | 2010-12-30 |
20100330041 | Viral-based antimicrobial agent use in ethanol production - A process of controlling unwanted microorganism contamination in the fermentation of mash to form ethanol, particularly to control | 2010-12-30 |
20100330042 | Use of Proinsulin for the Preparation of a Neuroprotective Pharmaceutical Composition, Therapeutic Composition Containing it and Applications Thereof - The present invention relates to the use of a compound that induces the activity of proinsulin, preferably human proinuslin, for the preparation of a medicinal product or pharmaceutical composition for the prevention and treatment of neurodegenerative conditions, disorders or diseases involving programmed cell death, preferably neurodegenerative pathologies of the central and peripheral nervous systems, and, more preferably, of the heredodegenerative diseases known as retinosis pigmentosa. The activator compound may consist of a chemical molecule, a peptide, a protein or a nucleotide sequence. | 2010-12-30 |
20100330043 | GPR125 AS A MARKER FOR STEM AND PROGENITOR CELLS AND METHODS USE THEREOF - The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof. The present invention also provides methods of detecting cancer cells based on GPR1 25 expression, and methods of targeting therapeutic agents to cancer cells to GPR125-positive cancer cells. | 2010-12-30 |
20100330044 | MESP1 AS A MASTER REGULATOR OF MULTIPOTENT CARDIOVASCULAR PROGENITOR SPECIFICATION AND USES THEREOF - A method for differentiating or promoting or inducing differentiation of stem cells into pluripotent cardiovascular progenitors (MCPs) by transiently inducing the expression of a single gene, namely Mesp1, is disclosed. Cells obtained by the method and their uses in research and clinical settings are also disclosed. Using genome wide transcriptional analysis, the inventors found that Mesp1 rapidly activates and represses a discrete set of genes, which form potential new targets for both therapy and for the identification of MCPs. Insights into the molecular mechanisms underlying the earliest step of cardiovascular specification and potential methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans are provided. | 2010-12-30 |
20100330045 | Mesenchymal precursor cell - A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1. | 2010-12-30 |
20100330046 | HUMAN SKIN SUBSTITUTES EXPRESSING IL-12 - The present invention relates generally to compositions for treating patients that have skin cancer or have recently had skin cancers removed. More specifically, the present invention provides human skin substitutes engineered to express exogenous IL-12 and compositions and methods for making human skin substitutes engineered to express exogenous IL-12. In addition, the present invention provides methods for treatment of sites on a patient where skin cancers have been removed with human skin substitutes engineered to express exogenous IL-12. | 2010-12-30 |
20100330047 | Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor - Methods of forming ex vivo cell cultures comprising differentiated mesenchymal lineage cells are disclosed. These methods comprise a) providing a cell culture comprising a plurality of mesenchymal stem cells (MSCs); b) subjecting the MSCs to hypoxic conditions; and c) subsequent to b), subjecting the MSCs to normoxic conditions. Enhanced differentiation of various mesenchymal lineage cells can be achieved for mammalian cells such as murine cells or human cells. | 2010-12-30 |
20100330048 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 2010-12-30 |
20100330049 | METHOD FOR GENERATING ISLET BETA CELLS FROM DEDIFFERENTIATED EXOCRINE PANCREATIC CELLS - The present invention relates to an in vitro method for generating insulin-producing beta cells from a population of mammalian cells comprising dedifferentiated exocrine pancreatic cells. The method comprises the step of culturing said dedifferentiated exocrine pancreatic cells in a culture medium in the presence of at least one agent that is able to inhibit the Notch 1 signaling pathway in said dedifferentiated exocrine pancreatic cells, and at least one ligand of the gp130 receptor and/or at least one ligand of the EGF receptor. The invention further provides a population of mammalian pancreatic cells comprising insulin-producing beta cells obtainable by the present method and uses thereof in a pharmaceutical composition for treating type 1 or type 2 diabetes. | 2010-12-30 |
20100330050 | USE OF HUMAN STEM CELLS AND/OR FACTORS THEY PRODUCE TO PROMOTE ADULT MAMMALIAN CARDIAC REPAIR THROUGH CARDIOMYOCYTE CELL DIVISION - The present invention relates to methods and compositions for stimulating the proliferation of cardiomyocytes for enhancement of cardiac repair. The invention is based on the discovery that upon contact with stem cells, or conditioned media derived from said stem cells, terminally differentiated cardiomyocytes can be stimulated to enter the cell cycle. Additionally, scaffolds capable of attracting stem cells to the area of implantation have been shown to induce cardiomyocyte proliferation. The present invention further relates to the discovery that the Wnt-5A ligand, which binds to the frizzled receptor (fz), functions to stimulate cardiomyocyte proliferation. The methods and compositions of the invention may be used in the treatment of cardiac disorders including, but not limited to, myocardial dysfunction or infarction. The invention further relates to screening assays designed to identify compounds that modulate the proliferative activity of cardiomyocytes and the use of such compounds in the treatment of cardiac disorders. | 2010-12-30 |
20100330051 | POLYPEPTIDE HAVING AN IMPROVED CYTOSINE DEAMINASE ACTIVITY - The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity. | 2010-12-30 |
20100330052 | Use of Mesenchymal Stem Cells for Treating Genetic Diseases and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 2010-12-30 |
20100330053 | MIXED-CELL GENE THERAPY - The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect. | 2010-12-30 |
20100330054 | PREPARATION, USE OF PREPARATION FOR TREATMENT, AND METHOD OF TREATMENT OF INTESTINAL INFECTION - A preparation for use in the treatment of | 2010-12-30 |
20100330055 | DISEASE RESISTANCE ENHANCER FOR PLANTS AND METHOD OF CONTROLLING PLANT DISEASE BY USING THE SAME - Infection of pathogens is controlled by inducing disease resistance with a method of treating a plant with a composition of an acidic heat-treated solution of microorganisms. | 2010-12-30 |
20100330056 | ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION - A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described. | 2010-12-30 |
20100330057 | METHOD OF EVALUATING HUMAN DENTRITIC CELLS AND HUMAN CELL IMMUNOTHERAPEUTIC AGENT - The invention provides a method of evaluating the antigen presentation potential of human dendritic cells by administering α-galactosylceramide-pulsed human dendritic cells to a non-human mammal; collecting a sample containing NKT cells from the non-human mammal; and detecting the activation of NKT cells present in the sample. The invention further provides an agent for human NKT cell immunotherapy, which contains human dendritic cells that have been assessed by the aforementioned method as those possessing an antigen presentation potential for NKT cells. | 2010-12-30 |
20100330058 | CHEWABLE DRUG - A chewable composition for delivering pharmaceutical compounds. The chewable composition includes a drug delivery vehicle and an active pharmaceutical ingredient. The delivery vehicle may include an organic or non-organic gummy candy. The active ingredient may include an over-the-counter drug or a prescription drug to provide a desired effect on the user. In addition to the active pharmaceutical ingredient, the chewable composition may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, amino acids, and digestive enzymes. | 2010-12-30 |
20100330059 | CHIMERIC FACTOR VII MOLECULES - The present invention relates to chimeric Factor VII polypeptides and methods of using the same. | 2010-12-30 |
20100330060 | GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2010-12-30 |
20100330061 | Methods and Devices for Treating Lung Dysfunction - Methods and devices useful for treatment of lung conditions resulting from dysfunction of normal pulmonary physiology. | 2010-12-30 |
20100330062 | KLOTHO PROTEIN AND RELATED COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER - Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 2010-12-30 |
20100330063 | STEM-LIKE CELLS, METHOD FOR DE-DIFFERENTIATING MAMMALIAN SOMATIC CELLS INTO STEM-LIKE CELLS, AND METHOD FOR DIFFERENTIATING STEM-LIKE CELLS - A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from embryos or fetuses, and without the need of potentially harmful transfecting vectors. Stem-like cells created by the present invention can be induced to differentiate into terminally differentiated adult somatic cells, such as, for example, neuronal cells. | 2010-12-30 |
20100330064 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 2010-12-30 |
20100330065 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2010-12-30 |
20100330066 | Methods for Use with Baff Antagonists - BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample. | 2010-12-30 |
20100330067 | Compounds and Methods for the Modulation of Toll-Like Receptor Function - The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression Toll-like Receptor 4 mediated activation of the immune system. The invention further provides screening assays to identify compounds which have utility in the foregoing compositions and methods. | 2010-12-30 |
20100330068 | MONOMERIC VHH DOMAIN DERIVED FROM ANTI-VP6 CAMELID ANTIBODIES, DIMERIC DOMAIN, IMMUNISATION METHOD, ROTAVIRUS DETECTION METHOD, COMPOSITION, PREVENTION AND TREATMENT METHODS FOR ROTAVIRUS INFECTIONS - Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus. | 2010-12-30 |